Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
about
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study GroupIn vitro and in vivo effects of doxycycline on Toxoplasma gondiiRemarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondiiIn vitro effects of folate inhibitors on Toxoplasma gondiiSynergistic effect of clindamycin and atovaquone in acute murine toxoplasmosisIn vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondiiPotent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolateEvaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replicationComparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycinToxoplasma gondii cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase.Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.Importance of nonenteric protozoan infections in immunocompromised people.In vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia Jack.Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity.In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondiiPyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii.Human antiprotozoal therapy: past, present, and future.Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patientsTrimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactionsUsefulness of stereotactic biopsy and neuroimaging in management of HIV-1 Clade C associated focal brain lesions with special focus on cerebral toxoplasmosis.Opportunistic infections in HIV-infected patients.Treatment of acute experimental toxoplasmosis with investigational poloxamersToxoplasma gondii: susceptibility and development of resistance to anticoccidial drugs in vitro.Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures.Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosisTemporal and spatial distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in vivoBiochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from Toxoplasma gondiiReduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound.Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDSComparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.Antileishmanial Activity of Liposomal Clarithromycin against Leishmania Major Promastigotes.Si-Accumulation In Artemisia annua Glandular Trichomes Increases Artemisinin Concentration, but Does Not Interfere In the Impairment of Toxoplasma gondii Growth.Toxoplasma encephalitis in AIDS patients in São Paulo during 1988 and 1991. A comparative retrospective analysis.Renal ultrasonic findings in sulphadiazine-induced renal failure.Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii.Comparative study on the antioxidant and anti-Toxoplasma activities of vanillin and its resorcinarene derivative.Cerebral toxoplasmosis in Danish AIDS patients.Extensive brain masses and cavitary lung lesions associated with toxoplasmosis and acquired immunodeficiency syndrome.
P2860
Q24519019-BCCBCA10-44E0-4269-8BF4-C8FDC880B371Q28335472-9D2361D5-F0E8-4DFD-947E-EE9DAC71310CQ28335576-D41257E9-6305-4CF1-8596-7690F6EC0C8DQ28342121-799348A9-2783-422D-8FDF-1B4691426120Q28343549-7092FF81-8566-4D2B-AEDD-F0CFD98EFEF4Q28359823-A54D904F-AA59-4128-95D0-39DE1CC8DFA2Q28360226-E4F71DB5-7F26-46FF-8CC6-DDC3FBD7C530Q28748825-F30FC567-4EB4-4351-BBF7-E560286B515EQ33746997-DDAD2B4E-FCAD-498C-AC07-860E4206E12CQ33904366-87DC6E6D-3F0A-4C98-ADCF-EBC3309A68C6Q34105538-66275FAA-E891-4505-881E-9ADCB0C63B09Q34189873-673307D5-F7FA-4D85-8F1E-F6589B407F09Q34332413-4A610EF3-5ACC-44A3-AE07-67AFEA453718Q35088834-D95E7347-ABDC-4A9B-A688-0A27D76743E8Q35116242-3C0400CC-4A31-4984-BBF9-6E72AB92C45FQ35124802-76FC1FD9-12C6-41CD-8813-09E447688D18Q35354962-B43A8847-64BD-4157-A00A-13A4B565335EQ35535171-0E1ED30E-99E5-4665-A443-0E170DB72192Q35547734-CAF60CAB-1C76-482C-8643-95A9B533EE1FQ35690237-EB605E40-70ED-4116-8C60-F701BE4F1EEDQ35789498-67EC8811-2889-46B4-8E73-93BF0AABCD3BQ35893214-73BCAA30-D07F-4A04-8B78-F8B915AEDDF8Q35899606-55B4E7EA-DAE6-49E2-B635-394392D3A648Q35899924-8E7B9688-EABC-43B9-B4D2-C10C4FB51146Q36232048-55CDA426-F320-4726-9408-B078E9965E79Q36754982-7A7CD67A-B5A6-4994-9005-AB7E15A0BDC7Q36758482-E0265E62-7EA5-4EDA-B01F-7EE6CB841D1EQ36804253-99A29B9A-A11A-4C47-8B52-7CEA6A521330Q37374814-32E70DF3-43BC-4F07-9FA5-3430C6180ED0Q38833635-7B6AAB75-2A4C-495B-9DDF-06CBD04FCE10Q39782411-E437EE19-EDB5-451E-A3CB-FAEC3FCFC91EQ39866037-6C41DD3A-4D53-4B80-A95F-335C37059E08Q40462418-D0DA84F8-E38F-43E9-8418-79BCDB69D673Q40512307-D00F9645-52A1-466D-8702-B24B7FC9363EQ40618750-D61F10C2-93CF-42EC-B582-8C07DA439A50Q42551108-57AAEFCA-A2CE-4F69-8967-A9258C76AE73Q44894421-050A8E9B-8F44-4C55-AFEE-7AA357257DBBQ47866173-02A244C6-D64B-4C06-9E31-54957C7B121FQ50544913-F6C50302-193A-4A6C-ACE8-7C9E00B40E1DQ51843581-A0D08777-1273-4F29-8971-FEF1BC8978F6
P2860
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
description
1987 nî lūn-bûn
@nan
1987 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@ast
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@en
type
label
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@ast
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@en
prefLabel
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@ast
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@en
P1476
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
@en
P2093
Haverkos HW
P304
P356
10.1016/0002-9343(87)90151-3
P407
P577
1987-05-01T00:00:00Z